Understand the ingredients, devices and treatment techniques you may hear about in a consultation. Open a card for an explanation, then read the full guide for evidence, limits and questions to ask.
Hyaluronic acid (HA) is a water-binding sugar found in body tissues. Molecular weight describes the mass of its polymer chains, often reported in kilodaltons (kDa). A formulation may use one range of chain sizes or a mixture. Molecular weight is a different property from HA concentration and from chemical cross-linking.
What the label does not tell you
High or low molecular weight alone does not establish how an injectable will perform in a particular person. Manufacturing, cross-linking, concentration and the finished gel’s properties also matter. Laboratory work shows that changing these variables can alter gel behaviour; it does not supply a universal clinical ranking. Evidence about a topical serum cannot simply be transferred to an injected gel.
Questions to bring
What exact HA formulation is being used and what is its intended purpose? Is it cross-linked, non-cross-linked or a different stabilised formulation? What clinical evidence supports this product for my proposed area and route? What change should I realistically expect beyond the molecular-weight claim?
Evidence and scope
Material characterisation helps explain formulation differences; it cannot, by itself, establish patient benefit or suitability.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Cross-linked and non-cross-linked HA
Cross-linking creates chemical connections between HA chains and can make an injectable gel persist longer. BDDE (1,4-butanediol diglycidyl ether) is one cross-linking reagent studied in HA fillers. Non-cross-linked HA does not have that same chemical network. Other approaches to stabilisation exist, so ask what the finished formulation contains rather than interpreting a marketing name alone.
What the label does not tell you
The reagent used during manufacture, the HA network it produces and any unreacted residual material are distinct questions. In a laboratory comparison of four BDDE gels, conventional measurements did not neatly track the chemistry and hydration changed the ranking of their properties. A cross-linking percentage is therefore not a universal durability or safety score. The exact product’s clinical evidence and instructions still matter.
Questions to bring
Which stabilisation or cross-linking approach does this formulation use? Can you explain why its finished gel properties fit the intended area? What product-specific safety, impurity and clinical data are available? What are the options and limitations if reduction or removal becomes necessary?
Evidence and scope
The chemistry paper is an in-vitro material study, not a head-to-head clinical result or a recommendation of a brand.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Calcium hydroxylapatite (CaHA)
Calcium hydroxylapatite (CaHA, also called calcium hydroxyapatite) is a mineral used as particles suspended in a carrier gel. It differs from hyaluronic acid. Certain formulations are used for volume or contour and are also discussed for collagen-related effects. The precise formulation and proposed use should be identified before those claims are applied to you.
What the label does not tell you
Undiluted, diluted and hyperdiluted treatments are not interchangeable promises. The ingredient name does not establish that the planned dilution, injection site or technique is authorised or supported. The American Society for Dermatologic Surgery specifically excludes lip augmentation from the uses of CaHA described on its patient page. Do not assume that every filler can be used in the lips or reduced in the same way as HA.
Questions to bring
Is the aim volume, contour or a skin-quality change and what supports that aim? Does the product’s intended use cover this site and proposed preparation? How would nodules or a vascular complication be recognised and managed? What are the limitations if I later want the material reduced or removed?
Evidence and scope
Regulatory indications belong to a product and jurisdiction; they do not apply automatically to every CaHA preparation. US FDA approval applies to an exact product and indication; authorisation in the treatment country must be checked separately.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Polynucleotides and PDRN
Polynucleotide (PN) and polydeoxyribonucleotide (PDRN) describe DNA-based preparations discussed in tissue research and aesthetic treatments. These names appear across different materials and delivery methods. Ask for the full ingredient name, source and formulation; a generic label such as a regenerative injectable does not identify what is being administered.
What the label does not tell you
A small randomised split-face trial compared one PN injectable with non-cross-linked HA in the eye area. Some measured outcomes favoured PN, while overall aesthetic scores did not differ significantly. Its 27 participants cannot establish all uses, all formulations or long-term rare risks. A separate PDRN combination study used cells and an animal model; it does not establish that injecting PDRN improves human skin. Wound-healing findings also do not automatically prove cosmetic benefit.
Questions to bring
Is this PN, PDRN or a combination and what else does it contain? What is the source material and does my allergy history affect suitability? Is the evidence for this exact preparation, route and area? What benefits remain uncertain and what reactions need follow-up?
Evidence and scope
Aesthetic evidence is formulation-specific and still developing. Avoid claims that a PN trial proves a PDRN product or that absence of serious events in a small study proves absence of risk.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Succinic acid in aesthetic treatments
Succinic acid and its salts, including sodium succinate, are discussed as ingredients in some HA-based skin treatments. Succinic acid participates in cellular metabolism, but a substance occurring in the body does not establish that injecting a particular preparation is beneficial or appropriate.
What the label does not tell you
A 2025 study of HA plus succinic acid reported changes in cultured human skin cells and adipocytes. It was a laboratory study with industry-employed authors; its authors expressly called for future clinical studies. It cannot establish the degree of visible improvement, treatment durability or patient safety. Evidence for the complete formulation should also distinguish the contribution of succinic acid from HA, the procedure itself and other ingredients.
Questions to bring
Does the formulation contain succinic acid or a succinate salt and what else is in it? Which controlled human studies support this exact injectable and intended result? What is authorised locally for this preparation and route? What uncertainty, side effects and alternatives should I consider before choosing it?
Evidence and scope
Biological plausibility and cell-culture results are not established clinical efficacy. This research does not justify a claim that the treatment reverses ageing or restores facial fat.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Deoxycholic acid (DCA)
Deoxycholic acid (DCA) is a cytolytic medicine: it disrupts cells. In the United States, approved deoxycholic acid injections are used in adults to improve moderate-to-severe fullness from submental fat, the fat beneath the chin. That authorisation does not cover treatment of fat throughout the body.
The FDA’s September 2026 warning states that injection outside the submental region is unapproved and not recommended. Serious complications have been reported after such use. Even use under the chin can cause problems including nerve injury, difficulty swallowing and persistent injection-site nodules or masses. A label saying fat dissolving does not identify a medicine, prove its authorisation or establish that the proposed area is appropriate.
Questions to bring
What is the exact drug and is this use authorised in the treatment country? Is the fullness actually suitable submental fat rather than another problem? How will you explain nerve, swallowing and injection-site risks? Who will assess persistent swelling, nodules or an uneven smile after treatment?
Evidence and scope
FDA restrictions described here concern the United States. Authorisation in the treatment country must be checked independently.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Botulinum toxin formulations
Botulinum toxin medicines temporarily reduce muscle activity by interfering with nerve signalling. They are used for certain movement-related lines and for other medical indications. They differ from dermal fillers, which add or restore volume. Identify the exact active substance and medicine rather than treating the generic term as one uniform product.
What the label does not tell you
The potency units of different botulinum toxin preparations are not interchangeable. A lower price per unit is therefore not a meaningful comparison without knowing the formulation and treatment plan. Authentic supply, storage and administration matter. In the United States, these medicines carry a boxed warning about spread of toxin effects; swallowing or breathing difficulties after treatment require immediate medical attention.
Questions to bring
What is the exact medicine and active substance? Does its local authorisation cover the proposed treatment? How was it sourced and will its batch be recorded in my notes? How do my medicines or muscle and nerve conditions affect the plan? Who do I contact for unexpected weakness, asymmetry or other reactions?
Evidence and scope
Safety information and approved uses differ between formulations. Ask for the patient leaflet for the exact medicine being proposed.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Radiofrequency: pulses and treatment modes
Radiofrequency (RF) devices use electrical energy to create tissue heating. Surface RF and RF microneedling deliver it differently: the latter uses small needle-like electrodes entering the skin. Terms such as monopolar, bipolar, pulsed or super-pulsed describe aspects of the system or delivery; they are not an ingredient or a universal clinical quality scale.
What the label does not tell you
Super-pulsed RF appears in an older uncontrolled study of one surface device. That finding cannot establish superiority of every system using the phrase and should not be applied to needle-based RF. The FDA’s 2025 RF microneedling communication describes reports of burns, scarring, fat loss, disfigurement and nerve damage. It recommends an appropriately trained licensed provider and says these devices should not be used at home.
Questions to bring
What device, handpiece and treatment mode are planned? Will energy be applied at the surface or through needles? What supports this device’s use for this area and my goal? How will you assess the risk of unwanted fat loss and protect underlying tissues? What monitoring, recovery advice and complication pathway are provided?
Evidence and scope
Pulse terminology needs verification in the context of the exact device. A marketing label or a single uncontrolled study does not establish a safety or efficacy ranking.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Microneedling: needle depth and cartridges
Microneedling uses small needles to create controlled punctures in skin. Needle length, the device’s selected penetration setting, treatment area and whether RF energy is added are separate details. A larger number is not automatically more effective or more appropriate. Needle settings belong in a clinician’s individual plan rather than a home-use recipe.
What the label does not tell you
In the United States, the FDA has legally authorised specific devices for particular uses. It has not approved microneedling devices to deliver cosmetics, medicines, vitamin solutions or blood products into the skin. Evidence for conventional microneedling should not be transferred to RF microneedling or to a cocktail applied during needling. A cartridge should be new for each patient and each session; cleaning does not make its reuse safe.
Questions to bring
Which device and cartridge will be used and what is it authorised for? Why is the planned penetration appropriate for this site and goal? Will a new cartridge be opened for this session? Are RF or added substances involved and what separately supports them? What are my infection, pigment-change or scarring risks?
Evidence and scope
Depth is a practitioner-selected parameter, rather than a setting to copy for home use. Authorisation and evidence for a device do not automatically cover additional products used with it.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Laser types and wavelengths
Laser wavelength is expressed in nanometres (nm), not as a needle length or a depth of treatment. Familiar examples include CO₂ at 10,600 nm, Er:YAG at 2,940 nm, Nd:YAG at 1,064 nm and alexandrite at 755 nm. These examples describe different laser systems; they are not a recommendation for your skin or a complete list.
CO₂ / carbon dioxide laser
CO₂ systems at 10,600 nm are established resurfacing examples. Full-field and fractional treatment differ in delivery. The name alone does not determine the intensity or recovery.
Er:YAG / erbium:YAG laser
Er:YAG at 2,940 nm is a resurfacing example. It is different from erbium:glass systems. The practitioner should identify the exact laser, delivery mode and planned tissue effect.
Nd:YAG / neodymium:YAG laser
Nd:YAG systems commonly use 1,064 nm; some also generate 532 nm light through frequency doubling. Long-pulsed, Q-switched and picosecond applications have different targets and treatment plans.
Alexandrite laser
Alexandrite at 755 nm is one laser family. The exact pulse mode, target, skin tone and cooling plan matter; the wavelength is not a universal suitability rating.
Diode lasers
Diode describes a semiconductor laser family with different wavelengths. A familiar hair-reduction wavelength such as 808 nm does not define every diode device or every application.
Fractional, full-field and pulse modes
Fractional describes a pattern of treatment zones and can be ablative or non-ablative. Q-switched, picosecond and long-pulsed describe aspects of pulse delivery. Picosecond systems can also be Q-switched; these labels are not mutually exclusive laser ingredients.
Questions to bring
What laser, wavelength and treatment mode are you proposing? What is the target: pigment, vessels, hair or skin texture? Why is this approach appropriate for my skin tone, recent tan and history? What eye protection, aftercare and expected healing are needed? How does the plan address pigment change, burns and scarring?
Evidence and scope
Regulator device records verify technical examples for specific systems. They do not make every use of that wavelength appropriate or demonstrate comparative superiority.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Intense pulsed light (IPL)
Intense pulsed light (IPL) uses a flashlamp to produce pulses across a range of wavelengths, with filters selecting the delivered light. A laser works differently. IPL and laser services may be grouped on clinic menus, but those names should not be used interchangeably. IPL may be proposed for different targets depending on the system and application.
What the label does not tell you
The term IPL does not identify the chosen filter, pulse sequence or goal. A single-subject study of treatment endpoints found that changes in wavelength selection and pulse parameters altered the skin response. That reinforces why a general light-treatment name cannot establish your risk or expected result. The device’s intended use, practitioner experience, your skin tone and recent sun exposure should be discussed together.
Questions to bring
Is this IPL or a laser and what exact system is used? What is the intended target and why is this approach suitable? Which factors in my skin history or medicines need a different plan? What eye protection and sun precautions are required? What discomfort, pigment changes or burns should prompt contact?
Evidence and scope
The endpoint study illustrates parameter effects in one person, rather than broad clinical efficacy or safety. IPL is not a laser and its wavelength range alone cannot establish which device is preferable.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Treatment subtype
Lip augmentation with fillers
Lip augmentation uses an appropriate injectable dermal filler to alter fullness, shape or definition. It differs from lip revitalization with topical boosters and cosmetic microneedling, which has surface hydration or texture goals. Ask which aim and exact route your proposed treatment involves.
What the label does not tell you
Not every HA formulation is intended for lips and not every filler material has the same uses. Ask about the exact product and the proposed change. Early swelling can make the initial appearance different from the settled result, so agree on review timing. Bruising, swelling and lumps can occur; accidental injection into a blood vessel can cause serious injury. Any proposed reduction or removal also has limits and risks.
Questions to bring
Are we aiming for volume, shape, definition or another change? Is this exact filler authorised locally for the proposed lip use? How do previous filler, cold sores or allergies affect the plan? When will we judge the settled result and what would prompt an earlier review? What is your emergency plan for unusual pain, skin colour changes or visual symptoms?
Evidence and scope
Lip hydration and lip volume are different goals. Discuss the parent dermal-filler risks and the exact HA formulation before choosing a treatment. Product authorisation varies by country and intended use.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Diglucosyl gallic acid (DGA)
Diglucosyl gallic acid (DGA) is a cosmetic ingredient studied for tone-related and antioxidant effects. It appears in some topical skincare and peel formulations. It is not interchangeable with trichloroacetic acid (TCA) or monochloroacetic acid (MCA) and does not define peel depth.
What research has tested
A 2022 study assessed laboratory antioxidant and tyrosinase-related activity and topical cosmetic emulsions in 20 volunteers. The findings concern the tested formulas, not every product containing the ingredient.
Its role in a peel formula
A manufacturer ingredient list includes DGA alongside glycolic and azelaic acid in a peel. This supports formulation inclusion rather than independent proof of all advertised benefits. The whole acid blend and instructions determine the procedure.
Questions about the formula
Ask which ingredients produce exfoliation, what DGA is intended to contribute and what evidence supports the finished formula. Ingredient identity alone does not establish the peel’s depth, results or suitability for your skin.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Treatment subtype
Lip revitalization and cosmetic microneedling
Lip revitalization is a broad treatment-menu term for goals such as smoother-looking or hydrated lips. Some providers pair a topical booster with cosmetic microneedling. The name does not define one formulation, needle procedure or proven result.
A different goal from augmentation
Injectable HA fillers can be used for lip fullness or shape when the exact product is intended for that use. A topical booster and microneedling do not place an equivalent filler gel. Early swelling should not be presented as proof of lasting augmentation. Explain whether your priority is dryness, texture, border definition or volume.
Match evidence to the lip and route
Ask which human data support the exact device, formula and lip area, including whether treatment involves the external skin, vermilion or mucosa. In the United States, microneedling devices are not approved to deliver cosmetic products into skin. A cosmetic label alone does not validate needling or injection.
Assess dryness before a procedure
Persistent chapping may need assessment and suitable daily care. Discuss cold sores, irritation and the aftercare plan. Lip-specific evidence matters; findings from facial skin or a different delivery method cannot automatically establish the benefit of this protocol.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Trichloroacetic acid (TCA)
Trichloroacetic acid (TCA) is a chemical peeling agent. TCA peel names identify an ingredient rather than a universal depth or recovery period. Professional assessment and the exact formulation matter.
Ingredient and depth
The concentration, formulation, number of applications and contact time influence how a peel acts. A percentage alone cannot establish a safe treatment or tell you how deeply every finished formula penetrates.
Different formulas need different evidence
A conventional TCA peel and a combined or modified acid formula are not interchangeable protocols. Product-specific instructions and evidence should support the proposed goal, area and skin type.
Risks and consultation
Burns, infection, pigment changes and scars are possible. Discuss your skin tone, recent sun exposure, medicines, recovery and aftercare with the practitioner. Strong chemical peels are not suitable for improvised home use.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Monochloroacetic acid (MCA)
Monochloroacetic acid (MCA, also called chloroacetic acid or MCAA) is used in some professional peel formulations. It is different from trichloroacetic acid, mandelic acid and the general term monocarboxylic acid.
Where the name appears
Manufacturers list MCA in certain professional peel formulas, sometimes combined with other acids. That establishes ingredient identity; it does not independently confirm every claimed aesthetic benefit.
Evidence must match the purpose
A randomized study of MCA concerned common and plantar warts. Those findings cannot establish facial-rejuvenation results. Ask for evidence and instructions for the exact professional peel being proposed.
A distinct chemical hazard
Chemical-safety guidance describes MCA as corrosive and potentially systemically toxic after exposure. Finished formulations and professional use need their own assessment. Do not treat an MCA product as interchangeable with a TCA peel or attempt a home protocol.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
HA bioremodelling and hybrid complexes
Bioremodelling and bioremodeling are terms used for certain HA-based approaches. Hybrid cooperative complexes combine high- and low-molecular-weight HA through a thermal process. This is a different type of stabilisation from covalent chemical cross-linking.
Three properties to separate
HA molecular weight, chemical cross-linking and thermal stabilisation describe different properties. The manufacturer describes hybrid-complex formation through hydrogen bonding without chemical cross-linking reagents. A marketing term does not identify every finished product.
Skin quality and volume goals
Classic skin-quality bioremodelling is discussed alongside skin boosters. It should not be assumed to act like a targeted volumizing filler. Different product variants can have different intended uses; ask whether the goal is skin quality, tissue support or volume correction.
Product-specific evidence
A 64-woman clinical study was open-label and uncontrolled. It cannot prove superiority over fillers or every other booster. The formulation, intended use and local status matter more than treating all hybrid HA products as one category.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Cryolipolysis / fat freezing
Cryolipolysis, commonly called fat freezing, uses controlled cooling to affect localized subcutaneous fat. It is a non-invasive body-contouring approach rather than liposuction or a weight-loss treatment.
Changes develop over time after treatment. The exact device, applicator and intended body area matter. Fat reduction does not automatically correct loose skin, cellulite or a medical cause of abdominal fullness.
Cooling-related risks
Pain, bruising, numbness and skin injury can occur. Paradoxical adipose hyperplasia means the treated fat enlarges instead of shrinking and may require surgery. Discuss conditions that make cold exposure unsuitable and the complication plan.
Device and country scope
Regulatory status belongs to a device and intended use, not every treatment called fat freezing. Ask about the planned area, expected change, follow-up and alternatives. US FDA guidance does not establish authorization in another country.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Treatment subtype
Liposuction
Liposuction, also called lipoplasty or suction-assisted fat removal, removes fat through a cannula during surgery. It belongs to both body contouring and aesthetic surgery. It differs from external cooling, heating or fat-dissolving injections.
Conventional suction, ultrasound-assisted and laser-assisted approaches are different techniques. Assisted liposuction still removes fat surgically; it is not equivalent to non-invasive ultrasound or light treatment.
Goals and suitability
Liposuction targets selected fat deposits rather than treating obesity. Skin laxity and cellulite may need a different assessment. Ask whether the proposed contour goal is realistic and how skin quality affects the expected appearance.
Recovery and risk
Anaesthesia, bleeding, infection, fluid changes, contour irregularities and serious complications require a surgical discussion. Recovery, compression, follow-up and emergency access should be explained by the operating team.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Glycolic acid (AHA)
Glycolic acid is an alpha-hydroxy acid (AHA). It is used in everyday skincare and in professional chemical peels. These uses involve different formulations and treatment plans; a familiar ingredient name does not make them interchangeable.
The formula shapes the effect
Glycolic acid can promote surface exfoliation. Its concentration, pH and other ingredients influence the effect. A headline percentage alone cannot establish the depth, recovery or suitability of a finished peel. Daily-use products should be used according to their own instructions.
What comparative evidence shows
A randomized split-face study in 20 people with acne compared professional glycolic and salicylic peels. Both improved acne without a significant difference in effectiveness during treatment. A small study of particular preparations cannot establish a universally best acid or predict results for pigmentation, scars or every skin type.
Discuss irritation and recovery
AHAs can increase sensitivity to sunlight. Discuss sun protection, existing skincare and when to pause or resume irritating products. Professional peels can cause burns, pigment changes and scarring. Ask about the actual formula, intended depth and the practitioner’s experience with your skin tone.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Lactic acid (AHA)
Lactic acid is an alpha-hydroxy acid (AHA) used in cosmetic products and professional peels. It is a different material from poly-L-lactic acid (PLLA), the polymer used in some injectable biostimulators. A lactic-acid peel belongs to chemical renewal.
Gentleness depends on the preparation
The ingredient may be discussed in hydrating skincare, but that does not establish that every professional lactic peel is hydrating or milder than another acid. Concentration, pH, other ingredients and the planned application influence exfoliation and tolerability.
Evidence is specific to the concern
A 2025 melasma trial randomized 40 patients and analyzed 34 who completed treatment. Both lactic and glycolic groups improved, with a larger reduction in melasma scores in the tested glycolic group. Reported side effects did not differ significantly. This small trial cannot predict every formula’s performance or establish a permanent cure for melasma.
Plan aftercare with the practitioner
Discuss pigment risk, recent sun exposure and existing skincare. Peels can cause irritation, burns, infection or scars. Ask for a recovery and sun-protection plan for the exact treatment. A daily-use lactic product and a professional peel need their own instructions.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Mandelic acid (AHA)
Mandelic acid is an alpha-hydroxy acid (AHA) used in skincare and professional peel formulations. It can also be combined with other ingredients, such as salicylic acid. Mandelic acid and monochloroacetic acid (MCA) are different ingredients.
A reputation is not a suitability test
Mandelic peels are often discussed for tolerability. The actual formulation, skin condition and treatment plan still matter. A gentler marketing description cannot establish suitability for every sensitive skin or eliminate pigment and irritation risks.
What the acne study found
A randomized trial in 50 people with mild-to-moderate facial acne compared mandelic and salicylic peels. Overall acne-score improvement was similar and fewer adverse effects were observed with mandelic in that trial. These results concern the tested preparations; they do not establish universal superiority or guaranteed scar or pigmentation improvement.
Single-acid and combined formulas
A mandelic peel and a salicylic-mandelic combination have different compositions. Ask which ingredients are present and what evidence supports the planned use. Discuss existing irritation, medicines, your skin tone and written aftercare. Professional peels can cause burns, pigment changes, infection and scarring.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Salicylic acid (BHA)
Salicylic acid is commonly called a beta-hydroxy acid (BHA) in skincare. FDA notes that this familiar cosmetic label is not a precise chemical classification. Salicylic acid is used in some everyday acne products and professional peels, which have different formulations and instructions.
Familiar skincare does not define a peel
A daily-use salicylic product is different from a professional peel. The formula, concentration and application determine the experience. Familiarity with an acne cleanser does not establish that a concentrated salicylic peel is suitable for home use.
What acne comparisons can tell us
Small randomized studies compared salicylic peels with glycolic or mandelic preparations. They reported acne improvement but do not establish one universally best acid. The studies’ participants, formulas and follow-up limit how their findings can be applied. Peels do not replace assessment of persistent acne or guarantee removal of deep scars.
Questions before treatment
Tell the practitioner about irritation, relevant allergies, medicines and other exfoliating products. Ask about the finished formulation and aftercare. Professional peels can cause burns, pigment changes and scars. Discuss experience with your skin tone and the sun-protection plan rather than assuming that a BHA label means low risk.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Mixed peels and Jessner formulations
Mixed, multi-acid and combination peels bring more than one ingredient or professional treatment step into a plan. A finished blend is different from applying separate products sequentially. Jessner is one formulation family, rather than a name for every mixed peel.
Classic and modified Jessner
Classic Jessner’s solution combines salicylic acid, lactic acid and resorcinol. Modified formulas vary: one primary study used a resorcinol-free version containing citric acid. Ask for the actual ingredient list. A shared name does not establish an identical formula, depth or recovery.
Blending and sequencing need context
A multi-acid formulation contains a blend; a sequential procedure may apply separate products, such as a Jessner preparation and TCA. Both require a professional plan. More ingredients or additional layers do not establish better results or less downtime. Evidence should match the formulation, concern and procedure proposed.
Compare the complete procedure
Ask which part of the procedure is intended to address your concern and why it is preferred over a single-agent peel. Discuss skin-tone experience, pigment risk, irritation and written aftercare. Chemical burns, infection and scars are possible. A treatment name should not be used as a home mixing or layering recipe.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Poly-L-lactic acid (PLLA)
Poly-L-lactic acid (PLLA) is a synthetic biodegradable polymer used in certain injectable particulate formulations. It is discussed as a collagen-stimulating material. It differs from hyaluronic-acid gels and from lactic acid used in chemical peels. Sculptra is one specific PLLA-containing product.
Gradual change and evidence limits
Immediate fullness can reflect the preparation fluid and swelling, rather than the final result. Improvement develops gradually. A randomized histology study in ten women reported tissue-remodeling findings, but its small sample cannot establish superiority over other treatments or detect uncommon complications. Discuss realistic goals and the complete treatment plan.
The product and treatment area matter
An inspected US Sculptra label includes specified facial wrinkle uses and facial lipoatrophy associated with HIV. It advises against injection into lip vermilion. These boundaries belong to that product and jurisdiction; they do not authorize every PLLA preparation or body area. Ask about the exact product and its intended use where you are treated.
Complications and correction
Bruising, swelling and discomfort can occur. Papules, nodules or granulomatous reactions may develop later. Rare vascular injury from filler injection can damage skin or vision and cause stroke. New visual symptoms or unusual severe pain need immediate clinical attention. PLLA has no specific reversal agent comparable to hyaluronidase for HA, so correction options should be discussed before treatment.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
PDO: polydioxanone threads
Polydioxanone (PDO) is an absorbable synthetic polymer used in sutures. It is not a sugar or polysaccharide. PDO can describe the material in different devices; it does not identify one lifting method or a guaranteed effect.
Material and thread design
A smooth PDO suture and a barbed lifting device share a polymer name but have different designs and intended actions. The projections and anchoring of a lifting thread matter alongside its material. Ask which exact device is proposed.
A suture clearance is not every lifting use
US FDA records illustrate the distinction. One inspected PDO device has a specific suspension indication; another PDO suture record explicitly excludes tissue lifting or support. These are product-specific examples. Ask whether the planned use and area are supported for the device in your treatment country.
Durability and complications
Breakdown of the polymer is different from the duration of a visible result. A 160-patient PDO series reported that early improvement declined over follow-up. It does not describe every modern device or a universal complication rate. Discuss contour irregularity, infection, extrusion and options if the result is unwanted.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
PLLA suspension threads
Poly-L-lactic acid (PLLA) is used in some physical suspension-thread devices. Sharing a polymer name does not make a thread procedure equivalent to an injectable PLLA biostimulator. The finished device and its components need their own explanation.
Thread and injectable are different forms
A physical filament can engage and support tissue through its design. Injectable PLLA preparations contain particles and use a different clinical approach. Their indications, complication discussions and correction options should not be transferred to a thread device just because both contain PLLA.
Identify every component
A primary study describes a device with a PLLA filament and PLGA cones. Another US suspension-device record describes lactide/glycolide resin in both components. PLGA is a copolymer and differs from pure PLLA. Ask about the actual filament, anchoring elements and product rather than relying on a broad polylactic label.
Mechanics do not prove long-term benefit
The cited mechanical study used cadaver tissue and computer modeling. It helps explain tissue engagement, but cannot establish clinical result duration or patient superiority. Ask for human evidence for the exact device, realistic expectations and a complication-management plan.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
PCL and copolymer threads
Polycaprolactone (PCL) is an absorbable synthetic polymer studied for thread applications. Some thread descriptions combine PLLA and PCL terminology; the actual device may use a copolymer rather than separate pure materials. Confirm the finished composition.
Pure polymer and copolymer
PLCL combines lactide and caprolactone units within a copolymer. It is a different composition from pure PCL or pure PLLA. Product descriptions such as PLLA/PCL need clarification from the device label and instructions. The material name does not identify whether a thread is smooth, barbed or otherwise anchored.
Research and its limits
A primary study compared PDO, PLLA and PCL threads in mice and examined tissue responses. Those findings do not establish a superior human lifting result, a safe treatment area or a guaranteed collagen effect. Human evidence must concern the actual device and procedure proposed.
What to ask before implantation
Ask for the exact product, composition, intended treatment area and local status. Polymer absorption and visible result duration are different measurements. Discuss the practitioner’s experience and how infection, visible threads, contour irregularity or an unwanted result would be assessed and managed.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Thread designs: smooth, barbed and cones
Material and design describe different properties of a thread. PDO, PLLA or PCL identifies a polymer; smooth, barbed and coned describes how a device is constructed. A consultation should explain both.
Unbarbed threads lack the projections or cones used for tissue engagement in suspension devices. They are often marketed for skin-quality effects, which need their own evidence. They should not be presented as producing the same mechanical lift.
Barbed / cog threads
Projections engage tissue to support repositioning. Direction, geometry and anchoring vary between products. Descriptions such as cog do not identify one device or establish that every placement and treatment area is supported.
Cone suspension sutures
Cone elements engage tissue along a filament. The filament and cones may use different polymers or copolymers. Mechanical studies help explain engagement; they do not establish how long every clinical result will last.
Match the design to the goal
Ask whether the intended goal is mechanical lifting or a proposed skin-quality change. Request the exact device identity, relevant human evidence and local intended use. No thread design eliminates the possibility of infection, visible threads, contour irregularity or an unsatisfactory result.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Ultrasound for body contouring
External ultrasound body contouring delivers sound-wave energy through the skin. Some systems target the fat beneath it; others aim to tighten loose skin. Terms such as HIFU or cavitation do not identify one procedure. Ask which tissue is being treated and what change the exact device is intended to produce.
Fat-targeted systems focus energy in subcutaneous fat and may use heating or mechanical disruption. Ultrasound for skin laxity targets different tissue depths to encourage a tightening response. Evidence for facial skin tightening does not establish abdominal fat reduction. Ultrasound-assisted liposuction is surgery with a cannula and has a separate recovery.
Read a claim in context
A randomized sham-controlled abdominal and flank study assessed waist circumference at 12 weeks. Results differed by energy level and by the analysis used. This supports a discussion about that protocol rather than a guaranteed change from every ultrasound device. A smaller waist measurement does not by itself show weight loss or explain how much fat changed.
Match the device to the area
Ask for the model, applicator, treatment depth and intended body area. In the United States, device authorization applies to particular uses and sites; it does not authorize the technology everywhere. Local status must be checked where treatment will take place. A familiar technology name is insufficient.
Recovery still needs a plan
Discomfort, swelling or bruising may affect comfort and appearance after fat-targeted treatment. Burns and nerve injury are possible complications. The practitioner should explain the expected reactions for the proposed settings, any activity advice and how persistent pain or a skin change will be assessed. An intact skin surface does not guarantee an easy recovery.
Decide what will be measured
Agree whether the goal is a localized fat bulge, loose skin or another concern. Ask for evidence that matches that goal and your treatment area. Clarify the session plan, assessment visit and total cost. Standardized photographs and comparable measurements can help discuss changes without relying only on a marketing image.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Low-level light for body contouring
Low-level light therapy is also called LLLT, low-level laser therapy or photobiomodulation. Body-contouring devices use low-dose light with an intended nonthermal action. This is a different approach from an external laser that heats fat or a laser used during surgical liposuction. The shared word laser can obscure those differences.
Photobiomodulation aims to influence cell activity without using heat to injure fat. It should not be described as external thermal fat destruction or suction removal. Red-light panels used for other purposes are not automatically equivalent to the body-contouring devices studied. Wavelength, dose, contact and treatment schedule all matter.
The outcome measured matters
A 67-participant sham-controlled study of a 635-nm system reported reductions in combined waist, hip and thigh circumference after a short treatment course. Those combined measurements are not the change at one site or proof of equivalent weight loss. A separate 650-nm study did not find a statistically significant reduction in ultrasound-measured fat thickness.
Limits to carry into the consultation
Different devices, schedules and follow-up periods make broad claims difficult to compare. A tape measurement can also be affected by factors other than local fat thickness. Ask whether the proposed device has controlled human evidence for your goal, how long any effect was followed and whether maintenance or lifestyle changes formed part of the study.
Low energy still requires care
Eye protection and a suitability check remain relevant. Discuss light-sensitive conditions, medications and any problem in the treatment area. Device design matters: the 650-nm study reported skin reactions including ulceration with its contact-panel system. This finding should not be generalized to every device, but it rules out a universal promise of no side effects.
Check the exact treatment offer
Request the model and patient information and check its local intended use. US clearance for a named device and site does not establish authorization in other countries. Agree on the session course, comparable photographs or measurements and when to review the outcome. Be cautious with claims of weight loss or a dramatic guaranteed contour change.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
External thermal laser body contouring
External thermal laser contouring uses applicators on the skin to deliver energy that heats the fat beneath it. Devices using approximately 1060-nm diode light are one example. No suction cannula is used in this external approach. Ask what the proposed model treats rather than relying on the ambiguous phrase laser lipolysis.
Three laser approaches need different explanations
Low-level photobiomodulation has an intended nonthermal action. External thermal treatment aims to heat localized fat while managing the skin surface. Laser-assisted liposuction introduces a device through an incision and removes fat surgically. A result or recovery description from one approach cannot be transferred to the other two.
Evidence for a particular protocol
A two-centre study enrolled 30 people for a single abdominal 1060-nm diode treatment and found reduced fat thickness on later ultrasound assessment. It had one treatment arm and no sham comparison. That design leaves uncertainty about how much of the measured change was caused by treatment and cannot support the same result for every device or patient.
A contour goal has limits
The intended discussion is a localized contour change. It is not a treatment for obesity or a substitute for assessing loose skin, muscle separation or other causes of fullness. Fat-thickness measurements, circumference and appearance describe different outcomes. Ask which outcome is realistic for your area and how the practitioner will assess it.
Comfort and skin protection matter
Treatment can feel hot or uncomfortable. Redness, swelling and tenderness can follow; heat-related injury is also possible. Ask about protective eyewear, surface cooling, skin assessment and the response to unexpected pain. Tell the practitioner about previous procedures, scars, skin reactions and medicines so the proposed plan can be assessed individually.
Allow time for assessment
A visible change is assessed after tissue responses develop, rather than immediately after the applicator is removed. Ask for the device’s follow-up plan, expected local reactions and any temporary activity advice. US authorization must match the exact device and body site; local authorization elsewhere needs its own check. A low-burden appointment is not a guarantee of no recovery needs.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Electrical muscle stimulation for the body
Electrical muscle stimulation, often called EMS or neuromuscular electrical stimulation (NMES), sends electrical pulses through electrodes on the skin to produce muscle contractions. Rehabilitation, fitness and aesthetic products may have different intended uses. This is distinct from magnetic stimulation, which induces a current in tissue using a changing magnetic field.
A muscle contraction does not itself show that nearby fat has been destroyed. Electrical stimulation for muscle rehabilitation or conditioning needs a different explanation from a fat-reduction procedure. TENS mainly targets nerve stimulation for pain-related uses and is not another name for NMES. Ask which function the proposed device is designed to provide.
A waist change is not proof of fat loss
A 60-participant randomized sham-controlled trial used an electrical stimulation programme over 12 weeks. Waist circumference decreased more in the EMS group than in the comparison group. However, changes in total and visceral abdominal fat measured by CT were not statistically significant. This distinction matters when a clinic presents a waist measurement as established local fat removal.
Intended use depends on the product
FDA guidance states that electrical muscle stimulators may temporarily strengthen, tone or firm muscles and that EMS devices have not been cleared for weight loss or girth reduction. This concerns US electrical stimulators and should not be substituted for the label of a magnetic or combination device. Check the proposed product’s status in the treatment country.
Discuss electrodes and suitability
Ask how the electrode placement and settings are chosen and which sensations are expected. Skin irritation, burns or unwanted electrical effects can occur. Implanted electronic devices require particular attention. Tell the practitioner about implants, medical conditions and treatment-area skin problems. A home-use product and a supervised medical device should not be assumed interchangeable.
Agree on a useful outcome
Clarify whether the goal is muscle conditioning, appearance or a particular contour measurement. Ask what controlled evidence supports the exact device and programme and whether changes last after sessions stop. Obtain instructions for skin care and activity if irritation or soreness occurs. A treatment course does not replace the health benefits of physical activity.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
Ingredient & technology guide
Magnetic muscle stimulation for the body
Electromagnetic muscle stimulation uses a changing magnetic field to induce electrical activity that makes muscles contract. Terms include EMMS and high-intensity focused electromagnetic treatment (HIFEM). These systems differ from electrode-based EMS or NMES. Some platforms also deliver radiofrequency heating; the added energy changes the treatment and the evidence needed to assess it.
Repeated contractions may change muscle tone or firmness. These outcomes are distinct from reducing the fat layer or correcting loose skin. Ask whether the applicator provides magnetic stimulation alone or includes thermal radiofrequency. Commercial terms and a strong contraction sensation do not establish a particular amount of muscle growth or fat reduction.
Combination evidence has a specific scope
A 72-participant sham-controlled abdominal study assessed simultaneous radiofrequency and HIFEM treatment and reported changes in ultrasound-measured fat and muscle thickness. These are findings for the combined protocol, not proof of the same fat effect from magnetic stimulation alone. Only 28 participants attended the six-month assessment and manufacturer advisory relationships were disclosed. Longer-term certainty is limited.
Interpret images and percentages carefully
Ask what was measured, where it was measured and whether comparison images used similar posture and lighting. Muscle thickness is different from functional strength; a percentage fat-thickness change is different from body-weight loss. A study of one device on the abdomen cannot establish the same benefit for another platform or body site.
Check suitability before contractions
Soreness or cramps can follow magnetic treatment. Tell the practitioner about implanted electronic devices and metal in the treatment area and request the exact contraindications. If the platform also heats tissue, ask about its additional skin and heat-related risks. The device’s patient information should guide assessment of your medical history and proposed area.
Plan recovery and review separately
Ask which local reactions could affect your comfort, exercise or clothing and what to do if symptoms persist. Agree when the result will be reviewed and whether further sessions may be proposed to maintain it. US authorization applies to a specific device and intended use; it does not establish authorization worldwide or a guaranteed dramatic contour change.
Sources describe specific products, studies or countries. They do not establish approval everywhere.
General education. Your clinician can assess your individual suitability. Rules depend on the treatment country; FDA references concern the United States. External sources may be in another language.
